GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevi Therapeutics Inc (NAS:TRVI) » Definitions » EV-to-FCF

TRVI (Trevi Therapeutics) EV-to-FCF : -15.36 (As of Mar. 17, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Trevi Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Trevi Therapeutics's Enterprise Value is $538.84 Mil. Trevi Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-35.09 Mil. Therefore, Trevi Therapeutics's EV-to-FCF for today is -15.36.

The historical rank and industry rank for Trevi Therapeutics's EV-to-FCF or its related term are showing as below:

TRVI' s EV-to-FCF Range Over the Past 10 Years
Min: -15.36   Med: 0   Max: 0.62
Current: -15.36

During the past 7 years, the highest EV-to-FCF of Trevi Therapeutics was 0.62. The lowest was -15.36. And the median was 0.00.

TRVI's EV-to-FCF is ranked worse than
100% of 416 companies
in the Biotechnology industry
Industry Median: 3.79 vs TRVI: -15.36

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-17), Trevi Therapeutics's stock price is $6.54. Trevi Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.440. Therefore, Trevi Therapeutics's PE Ratio (TTM) for today is At Loss.


Trevi Therapeutics EV-to-FCF Historical Data

The historical data trend for Trevi Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevi Therapeutics EV-to-FCF Chart

Trevi Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -0.43 -0.49 - -0.15 -0.31

Trevi Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.63 -0.31 -4.88 -4.51 -5.35

Competitive Comparison of Trevi Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Trevi Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trevi Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevi Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Trevi Therapeutics's EV-to-FCF falls into.



Trevi Therapeutics EV-to-FCF Calculation

Trevi Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=538.839/-35.087
=-15.36

Trevi Therapeutics's current Enterprise Value is $538.84 Mil.
Trevi Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trevi Therapeutics  (NAS:TRVI) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Trevi Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.54/-0.440
=At Loss

Trevi Therapeutics's share price for today is $6.54.
Trevi Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.440.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Trevi Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Trevi Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Trevi Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
195 Church Street, 16th Floor, New Haven, CT, USA, 06510
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Executives
Jennifer L Good director, 10 percent owner, officer: See Remarks 15 GREAT RING ROAD, SANDY HOOK CT 06482
David P Meeker director, 10 percent owner C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Thomas Sciascia 10 percent owner, officer: Chief Medical Officer 39 OLD RIDGEBURY RD. SUITE 11, DANBURY CT 06810
Lisa Delfini officer: Chief Financial Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FL. 14, NEW HAVEN CT 06510
Farrell Simon officer: Chief Commercial Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
David J Clark officer: Chief Medical Officer 131 HARTWELL AVE, LEXINGTON MA 02421
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025